This is a routine director sale following an option exercise, no material signal. Monitor for actual Form 4 filings to confirm whether the sale was executed. The small size relative to market cap and director status (not CEO/CFO) suggests no bearish read-through.
PYXS drugs
PYXS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 1 $2.85entry
- T+1 · 5mo ago −7.72%α −7.59% · $2.63
- T+5 · 4mo ago +7.72%α +7.46% · $3.07
- T+20 · 4mo ago +2.46%α +4.64% · $2.92
- T+60 · 8w ago +2.46%α −0.50% · $2.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Jakob Dupont filed a Form 144 on June 30, 2026, indicating intent to sell 35,000 shares of Pyxis Oncology common stock, valued at approximately $107,034. The shares were acquired via a stock option exercise on the same day. This is a routine director sale following an option exercise and does not signal a change in company fundamentals.
Key Facts
- Director Jakob Dupont filed Form 144 to sell 35,000 shares of Pyxis Oncology common stock.
- Estimated sale value is approximately $107,034 based on the filing date.
- Shares were acquired via stock option exercise on June 30, 2026.
- The sale is to be executed through Fidelity Brokerage Services LLC.
- The filing represents intent to sell, not a completed transaction.
Financial Impact
Proposed sale of 35,000 shares valued at ~$107K, representing ~0.06% of shares outstanding (based on 63.4M shares outstanding per filing).
Risk Factors
- Insider sale could be perceived negatively by retail traders despite routine nature.
- If additional insider sales cluster in coming weeks, it could signal reduced confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-004977 |
| Document: 0001959173-26-004977-index.html | 0001959173-26-004977 |
| Document: 0001959173-26-004977.txt | 0001959173-26-004977 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers